NCT02440100View on ClinicalTrials.gov

A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Healthy Adult Subjects and Healthy Elderly Subjects
Interventions
DRUG

PF-06648671

experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days

DRUG

Midazolam

commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671

DRUG

Placebo

Matching placebo which will be given as oral suspension, once a day for 14 days

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02440100 - A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects | Biotech Hunter | Biotech Hunter